Ziopharm Oncology (ZIOP) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results
February 25, 2021 4:05 PM ESTHeidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper; Search for Permanent CEO Initiated
Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory Role
James Huang Appointed Executive Chairman and Board Refreshment Completed
FDA IND Clearance Announced for Groundbreaking Library TCR-T Phase I/II Clinical Trial, Targeting Six Hotspot Mutations in KRAS and TP53
Further Details Provided on R&D Day on March 11 Including Participation of Dr. Steven Rosenberg, Dr. Carl June, and Dr. Scott Kopetz
... More